Literature DB >> 8198664

Neonatal adrenergic blockade following single dose maternal labetalol administration.

J M Klarr1, V Bhatt-Mehta, S M Donn.   

Abstract

A single 30 mg intravenous dose of labetalol given 20 minutes prior to cesarean delivery at 35 weeks of gestation for severe pregnancy-induced hypertension was associated with symptoms of beta-adrenergic blockade (hypoglycemia, bradycardia, hypotension) in preterm twins. The infants were subsequently found to have therapeutic labetalol concentrations (180 and 150 ng/mL) in umbilical cord blood. The pharmacology of transplacental labetalol is reviewed and potential mechanisms for neonatal beta-adrenergic blockade are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198664     DOI: 10.1055/s-2007-994563

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  5 in total

Review 1.  Drug-induced disorders of glucose metabolism. Mechanisms and management.

Authors:  J C Chan; C S Cockram; J A Critchley
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 2.  Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?

Authors:  S M Khedun; B Maharaj; J Moodley
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

3.  Adverse neonatal effects of maternal labetalol treatment.

Authors:  B N Crooks; S A Deshpande; C Hall; M P Platt; D W Milligan
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-09       Impact factor: 5.747

Review 4.  Use of medication for cardiovascular disease during pregnancy.

Authors:  Petronella G Pieper
Journal:  Nat Rev Cardiol       Date:  2015-12       Impact factor: 32.419

Review 5.  The Risk for Neonatal Hypoglycemia and Bradycardia after Beta-Blocker Use during Pregnancy or Lactation: A Systematic Review and Meta-Analysis.

Authors:  Rosalie de Bruin; Sarah L van Dalen; Shamaya J Franx; Viraraghavan V Ramaswamy; Sinno H P Simons; Robert B Flint; Gerbrich E van den Bosch
Journal:  Int J Environ Res Public Health       Date:  2022-08-04       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.